Elite in Netherton Syndrome

Waseem Qasim

Great Ormond Street Hospital For Children National Health Service Trust & University College London Institute Of Child Health
London, ENG, GB 
Elite in Netherton Syndrome
Great Ormond Street Hospital For Children National Health Service Trust & University College London Institute Of Child Health
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Waseem Qasim practices in London, United Kingdom. Mr. Qasim is rated as an Elite expert by MediFind in the treatment of Netherton Syndrome. His top areas of expertise are Netherton Syndrome, Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Primary Immunodeficiency (PID), and Bone Marrow Transplant.

His clinical research consists of co-authoring 101 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Netherton Syndrome.

Gender
Male

Locations

Great Ormond Street Hospital for Children National Health Service Trust & University College London Institute of Child Health
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
Enrollment Status: Completed
Publish Date: October 08, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 1 Less Clinical Trial

101 Total Publications

Long term outcomes of genome edited 'universal' CAR19 T-cells for relapsed/refractory B-ALL at a single pediatric centre.
Long term outcomes of genome edited 'universal' CAR19 T-cells for relapsed/refractory B-ALL at a single pediatric centre.
Journal: Blood advances
Published: March 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Qasim's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile